UPDATE - Reversing a Fortune: Lessons Learned From IGEN v. Roche

July 30, 2003 Advisory

On July 15, 2003, Wiggin & Dana issued a Client Alert summarizing the recent decision of the U.S. Court of Appeals for the Fourth Circuit (the Court), reversing nearly $490 million in damages awarded to IGEN International, Inc. after a six year legal battle with Roche Diagnostics GmbH over issues relating to a license agreement (the License Agreement). IGEN International, Incorporated v. Roche Diagnostics GMBH et al., 02-1537 (4th Cir., 2003). under the License Agreement, IGEN granted rights to Roche to develop and commercialize products comprising IGEN's proprietary electrochemiluminescence (ECL) technology.